(Press-News.org) The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. Details of the finding, from a clinical trial led by Johns Hopkins experts, are scheduled for presentation on Saturday, June 4 at the 2011 American Society of Clinical Oncology (ASCO) annual meeting (abstract #4532).
Currently, the drug is approved to treat fungal infections in nails and other organs. Serious side effects can include heart failure, and Johns Hopkins experts caution that itraconazole needs further study before it can be considered for prostate cancer treatment.
Identified as a potential anticancer drug after Hopkins scientists scoured a database of more than 3,000 FDA-approved drugs, itraconazole appears to block tumor blood vessel growth -- the only drug in its class to do so -- much like the anticancer drug bevacizumab (Avastin). The antifungal also disrupts a key cancer-initiating biological pathway called Hedgehog. Laboratory testing by Johns Hopkins scientist Jun Liu, Ph.D., has shown that human prostate tumors implanted in mice shrink when treated with itraconazole.
"The most effective therapy we have right now for metastatic prostate cancer is hormone therapy, and when it doesn't work, the next step is usually chemotherapy," says Emmanuel Antonarakis, M.D., assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. In a search for compounds that could put off chemotherapy, the Johns Hopkins team turned to itraconazole.
For the study, patients with prostate cancer that had spread to other organs and did not respond to hormone therapy were randomly assigned to receive low or high doses of itraconazole.
Over 24 weeks of daily treatment with oral itraconazole, the investigators tracked the length of time for each patient's prostate cancer to worsen (called progression-free survival). Evidence of worsening disease was measured by a 25 percent increase in their blood level of prostate specific antigen (PSA), a marker for prostate cancer.
Early in the trial, preliminary analysis of 17 men receiving low doses of itraconazole showed that only two of them (11.8 percent) had stable or declining PSA. Because of the limited response, no further men were given low doses of the drug.
However, 11 of 24 (48.4 percent) men taking high doses of itraconazole had stable or declining PSA levels lasting at least 24 weeks. In addition, nearly a third of men taking the high dose had PSA reductions of 30 percent or more. Metastatic prostate cancer patients receiving no treatment typically would worsen in eight to 12 weeks, according to Antonarakis.
The investigators also found that 12 of 14 men taking high doses of itraconazole had lower levels of circulating tumor cells present in their blood after therapy, compared with their baseline levels.
Seven patients experienced side effects, including low potassium, hypertension and fluid retention, but the problems were resolved with potassium replacement pills, anti-hypertension drugs, and diuretics.
"We also tested whether itraconazole acted as hormone therapy by tracking levels of testosterone and DHEA (a testosterone derivative) in the blood, and we found no reductions of either testosterone or DHEA," says Antonarakis. "This finding shows that itraconazole is not just another hormone therapy, and has a unique mechanism of action."
Antonarakis and colleagues next plan to examine blood and skin samples taken from study participants specifically to look for levels of proteins linked to tumor blood vessel formation and the Hedgehog pathway.
"With these results, we believe that high-dose itraconazole is worth studying in a larger group of men with advanced prostate cancer," adds Antonarakis.
INFORMATION: The clinical trial was funded by the Department of Defense (DoD) Prostate Cancer Research Program, the Commonwealth Foundation for Cancer Research, the David H. Koch Charitable Foundation, a 2009 American Society of Clinical Oncology (ASCO) Young Investigator Award granted to Antonarakis, and the National Institutes of Health/National Cancer Institute.
In addition to Antonarakis, other investigators participating in the research on behalf of the Prostate Cancer Clinical Trials Consortium included Amanda Blackford, Serina King, Anja Frost, Seun Ajiboye, Sushant Kachhap, Michelle Rudek, and Michael Carducci from Johns Hopkins; Elisabeth Heath from the Karmanos Cancer Institute; David Smith from University of Michigan, Ann Arbor; and Dana Rathkopf and Daniel Danila from Memorial Sloan Kettering Cancer Center.
END
A study in a special early online publication of Cell, a Cell Press publication, reveals a promising new slow-release compound that protects mice against the neurodegenerative effects of both Huntington's and Alzheimer's disease. The 'prodrug' known only as JM6 works through a pathway involved in the breakdown of the amino acid tryptophan.
Surprisingly, JM6 delivers those benefits even though it doesn't cross the blood-brain barrier and therefore cannot act directly on the brain.
"Most would have assumed that the drug would have to enter the brain to have an effect," ...
Thousands of events are scheduled across the nation to celebrate the joys and traditions that come with riding bicycles. While most events are geared to welcome spring and summertime activities, some, like the Bike Bonanza in downtown Salt Lake City, promote healthy living and efficiency. Another national event, the Ride of Silence, is dedicated to reminding people about bicycle safety and honoring those killed in bicycle accidents.
Each year since 2003, riders have gathered on the third Wednesday of May to bring awareness to the hazards bicyclists endure from motorists. ...
AUDIO:
University of Michigan School of Public Health researcher Stoddard's research shows a link between violent behavior and brain injury in youth.
Click here for more information.
ANN ARBOR, Mich.---Young people who have sustained a head injury during their lifetime are more likely to engage in violent behavior, according to an eight-year study from the University of Michigan School of Public Health.
Further, the research found that young people who suffered a recent ...
(SALT LAKE CITY)—Parents and health care providers can't always tell whether toddlers display signs of autism syndrome disorder (ASD), but new research from the University of Utah shows that a significant portion of at-risk children between 14-24 months can be identified through systematic screening by autism experts and providers working together.
Identifying children with ASD as young as possible is critical for the early intervention that can improve their lives and ability to function in the world. But a systematic way to do that has not been established, according ...
As the World Health Organisation suggests the E. coli outbreak in Germany is a strain never before seen in an outbreak – O104:H4 – laboratory science conducted at the University of Southampton indicates a role for copper in preventing the spread of such infections.
Professor Bill Keevil, Head of the Microbiology Group and Director of the Environmental Healthcare Unit at the University of Southampton, explains: "A study looking at copper's efficacy against new strains of E. coli has just been completed. Although it did not specifically look at O104, all the strains investigated ...
LOUISVILLE, Ky. – University of Louisville researchers are one step closer to helping millions of people whose salivary glands no longer work because of disease or damage from treatment of diseases.
The scientific finding of Douglas Darling, PhD, professor, Department of Oral Health and Rehabilitation, UofL School of Dentistry, and his team identified a protein sorting mechanism used by the salivary gland. The National Institutes of Health supported study published on-line first this week in the Journal of Dental Research.
The scientific discovery could form the ...
Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.
In the study, published recently in the journal ACS Chemical Biology, the scientists showed they could disrupt a specific interaction of a critical enzyme that would prevent cell death without harming other important enzyme functions.
The enzyme in question is c-jun-N-terminal kinase (JNK), ...
Wrong-site surgery is a one of the most preventable forms of medical malpractice because it is so unnecessary. It indicates sloppiness in procedure and a level of inattention to detail you would hope to never find in a surgeon or their staff.
While there are often explanations, there is never any excuse. It might be excusable in an emergency military hospital, with surgeons operating under a crush of battle injured patients, but it should simply never occur in a modern hospital.
A statement from the website of the American Academy of Orthopaedic Surgeons notes: "Wrong-site ...
The nation's system of freeing some terminally ill prisoners on grounds of compassionate release is so riddled with medical flaws and procedural barriers that many potentially medically eligible inmates are dying behind bars, say UCSF researchers in a new study.
The research, which calls for an overhaul of current practices, is published online this week in Annals of Internal Medicine.
"Current compassionate release guidelines are failing to identify seriously ill prisoners who no longer pose a threat to society, placing huge financial burdens on state budgets and contributing ...
The Fair Sentencing Act of 2010 (FSA) reduced what many have criticized as disproportionately harsh sentences for crack cocaine offenses. The sentencing ratio remains at approximately 18 to 1 for the amount of powder cocaine versus crack cocaine required to trigger the same penalty, but this is a significant reduction from a former ration of 100 to 1.
2007 Amendments
The federal sentencing guidelines were previously amended in 2007 in an effort to reduce the disparity between sentences for crack and powdered cocaine offenses. Although the sentencing guidelines were ...
